secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001628280-25-049236
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn Q3 net loss narrows to $15.8M; CFO Humer resigns; cash runway into 2028
-------------------------------------------------------------------------------

- CFO Kristian Humer resigns effective Nov 14, 2025 to pursue other opportunity; no disagreement with company.
- Q3 2025 net loss $15.8M vs $19.1M YoY; collaboration revenue $8.2M (vs $7.8M); R&D expenses $20.0M.
- Cash, equivalents, and marketable securities $180.3M as of Sept 30, 2025; provides cash runway into 2028.
- FHD-909 (SMARCA2 inhibitor) Phase 1 trial in SMARCA4-mutated NSCLC enrolling well; combination data with pembrolizumab and KRAS inhibitors.
- Selective CBP degrader IND-ready in 2026; EP300 degrader IND-enabling studies in 2026; ARID1B degrader advancing to in vivo POC in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828025049236/0001628280-25-049236-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828025049236/fhtx-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-049236

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer